# Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

> **NCT01059383** · PHASE2 · COMPLETED · sponsor: **Vecta Ltd.** · enrollment: 52 (actual)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DRUG:** VECAM 40/300
- **DRUG:** Esomeprazole 20 mg

## Key facts

- **NCT ID:** NCT01059383
- **Lead sponsor:** Vecta Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2012-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01059383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01059383, "Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01059383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*